You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
|
|---|---|
| Published in |
BMC Cancer, August 2018
|
| DOI | 10.1186/s12885-018-4692-z |
| Pubmed ID | |
| Authors |
Kyriakos P. Papadopoulos, Eytan Ben-Ami, Amita Patnaik, Denise Trone, Jianke Li, George D. Demetri |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 36 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 31% |
| Other | 3 | 8% |
| Lecturer | 2 | 6% |
| Student > Bachelor | 2 | 6% |
| Student > Ph. D. Student | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 12 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 25% |
| Biochemistry, Genetics and Molecular Biology | 5 | 14% |
| Nursing and Health Professions | 5 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Environmental Science | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 12 | 33% |